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Abstract
Introduction Structural uncertainty relates to differences
in model structure and parameterization. For many pub-
lished health economic analyses in oncology, substantial
differences in model structure exist, leading to differences
in analysis outcomes and potentially impacting decision-
making processes. The objectives of this analysis were
(1) to identify differences in model structure and parame-
terization for cost-effectiveness analyses (CEAs) compar-
ing tamoxifen and anastrazole for adjuvant breast cancer
(ABC) treatment; and (2) to quantify the impact of these
differences on analysis outcome metrics.
Methods The analysis consisted of four steps: (1) review
of the literature for identification of eligible CEAs;
(2) definition and implementation of a base model
structure, which included the core structural components
for all identified CEAs; (3) definition and implementation
of changes or additions in the base model structure or
parameterization; and (4) quantification of the impact of
changes in model structure or parameterizations on the
analysis outcome metrics life-years gained (LYG), incre-
mental costs (IC) and the incremental cost-effectiveness
ratio (ICER).
Results Eleven CEA analyses comparing anastrazole and
tamoxifen as ABC treatment were identified. The base
model consisted of the following health states: (1) on
treatment; (2) off treatment; (3) local recurrence; (4) met-
astatic disease; (5) death due to breast cancer; and
(6) death due to other causes. The base model estimates of
anastrazole versus tamoxifen for the LYG, IC and ICER
were 0.263 years, €3,647 and €13,868/LYG, respectively.
In the published models that were evaluated, differences in
model structure included the addition of different recur-
rence health states, and associated transition rates were
identified. Differences in parameterization were related to
the incidences of recurrence, local recurrence to metastatic
disease, and metastatic disease to death. The separate
impact of these model components on the LYG ranged
from 0.207 to 0.356 years, while incremental costs ranged
from €3,490 to €3,714 and ICERs ranged from €9,804/
LYG to €17,966/LYG. When we re-analyzed the published
CEAs in our framework by including their respective
model properties, the LYG ranged from 0.207 to
0.383 years, IC ranged from €3,556 to €3,731 and ICERs
ranged from €9,683/LYG to €17,570/LYG.
Conclusion Differences in model structure and parame-
terization lead to substantial differences in analysis out-
come metrics. This analysis supports the need for more
guidance regarding structural uncertainty and the use of
standardized disease-specific models for health economic
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analyses of adjuvant endocrine breast cancer therapies. The
developed approach in the current analysis could poten-
tially serve as a template for further evaluations of struc-
tural uncertainty and development of disease-specific
models.
Key Points for Decision Makers
• Structural uncertainty may have a significant impact
on the outcome of cost-effectiveness models.
• There is an urgent need for guidelines on handling of
structural uncertainty in cost-effectiveness analysis.
• Standardized disease-specific models in cost-effec-
tiveness analysis should be developed to improve the
consistency and relevance of health economic infer-
ences.
1 Introduction
Decision making for reimbursement of new drugs is
being increasingly supported by health economic analy-
ses. In order to derive informed decisions, it is important
to quantify the uncertainty associated with model pre-
dictions. Recently, recommendations have been published
by the Modeling Task Force from the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR), describing good research practices in handling
uncertainty [1]. The main sources of uncertainty
include methodological, parameter and structural uncer-
tainty [2].
Methodological uncertainty can be defined as differ-
ences between analysis methodologies. To decrease
methodological uncertainty, implementation of a reference
case has been recommended, which is a set of methodo-
logical practices intended to standardize economic evalu-
ations to improve comparability [3].
Parameter uncertainty is related to the precision of
model parameter estimation, which in turn depends on the
informativeness of the data that are used and the com-
plexity of the model that is being estimated. The impact of
parameter uncertainty can be evaluated using stochastic
simulations or sensitivity analysis [4, 5].
In this article, we consider structural uncertainty as
uncertainty associated with all aspects of model structure,
including health states and the specific relationships
between these health states, but also the mathematical form
of transition rates (e.g. constant, or time-varying according
to a specific function). Of note, the specific parameters that
are used for any mathematical expression can in turn be
associated with parameter uncertainty.
The reasons for differences in model structure, and thus
structural uncertainty, may be that some aspects of the
process being modelled represent different levels of rele-
vance, thereby justifying model simplifications. Alterna-
tively, in some cases, some data may not be available
although their inclusion could potentially still be relevant
for the analysis. Structural uncertainty deals specifically
with such assumptions or simplifications made in the
model structure.
In contrast to methodological uncertainty and parame-
ter uncertainty, structural uncertainty has only been
addressed to a limited extent in current health economic
guidelines [6–8], although it has been demonstrated that
the impact of structural uncertainty on analysis outcome
metrics can be of substantial magnitude. For instance,
Bojke et al. [6] showed how structural uncertainty
induced changes in outcome that could potentially impact
reimbursement decisions. Kim and Thompson [9] showed
that the impact of structural uncertainty on estimated
incremental cost-effectiveness ratios (ICERs) could be of
a similar magnitude to the impact of parameter uncer-
tainty. Both examples illustrate the potential impact of
structural uncertainty on public funding decisions, thereby
justifying the relevance of more research and guidance in
this area.
In the therapeutic area of oncology, small differences in
overall survival are typically observed between competing
treatments. Therefore, structural uncertainty could have a
major impact on the outcome of cost-effectiveness analyses
(CEAs) and associated decision making. Breast cancer is
the most common malignancy in women worldwide [10],
and many new drugs are currently in development for
treatment of breast cancer. Health economic analyses are
therefore of key importance to support selection and
decision making with respect to reimbursement decisions
on currently used and new therapeutic agents for breast
cancer. Endocrine therapy plays a key role in treatment and
management of hormone receptor-positive breast cancers
[11]. A number of recent reviews [12–16] have identified
up to 20 different CEAs comparing endocrine therapeutic
strategies, most of which included either tamoxifen or
anastrazole for treatment of hormone receptor-positive
adjuvant breast cancer (ABC). However, none of these
reviews specifically addressed the impact of structural
uncertainty for CEAs comparing endocrine breast cancer
treatments.
The objectives of the current analysis were (1) to
identify differences in reported structural models and
model parameterizations for cost-effectiveness analyses
comparing tamoxifen and anastrazole; and (2) to evaluate
and quantify the impact of identified differences in model
components on analysis outcome metrics.
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2 Methods
The analysis was performed in four steps:
1. Review of the literature for identification of eligible
CEAs;
2. Definition and implementation of a base model
structure, which included the apparent core properties
present for all identified CEAs;
3. Definition and implementation of changes or additions
in the base model structure or parameterization;
4. Quantification of the impact of differences in the
model structure or parameterizations on the analysis
outcome metrics life-years gained (LYG), incremental
costs (IC) and ICER. Optional changes or additional
model components that were identified are referred to
as M1, M2, … Mn.
All models were implemented as systems of ordinary
differential equations, using a previously developed
scripting framework for CEAs [17] based on the statis-
tical scripting language R (version 2.10.0) [18]. This
framework allowed straightforward and reproducible
implementation of different models and model compo-
nents in order to allow for an unbiased evaluation of the
impact of differences in model structure, fully excluding
potential influences of other sources of uncertainty. In
addition, this framework implements a modern multistep
ordinary differential equation solver algorithm, which
automatically adjusts the cycle length to adequate step
sizes, thereby eliminating the need to specify the cycle
length upfront and overcoming cycle length-induced bias
[17].
2.1 Literature Review
Eligible CEAs compared anastrazole and tamoxifen for
the treatment of early breast cancer and were imple-
mented using Markov models or ordinary differential
equation-based approaches. These CEAs were selected on
the basis of a previously conducted review [16] investi-
gating other methodological differences between CEAs of
anastrazole and tamoxifen, unrelated to structural uncer-
tainty. For each analysis, the structural model compo-
nents were extracted from the publications. Subsequently,
identified model components were categorized into two
groups: (1) structural model characteristics, e.g. health
states and associated transition rates; and (2) parameter-
ization of transition rates. For Markov models reporting
transition probabilities, these were converted into transi-
tion rate constants.
2.2 Definition and Implementation of the Base Model
Structure
On the basis of the identified model structures, a base
model was defined by including the health states that were
present in all different published models, thereby repre-
senting the core model structure of health economic models
for endocrine drug treatment of ABC. The base model was
not necessarily intended as a recommendation but only as a
reference point for alternative model structures.
Transition rate parameterizations for the base model were
selected by using the mathematically simplest possible
implementation as was described for the different identified
CEAs. For instance, when a certain transition rate was
included using a time-varying or a constant rate, the constant
rate was included in the base model. The parameter estimates
used for the base model were obtained from the most com-
plete report with respect to the availability of parameter
estimate values. The year of valuation was 2012, a 25-year
time horizonwas usedwith discount rates of 1.5 % for effects
and 4 % for costs, and the cycle length varied over time,
depending on the transition rate [17].
2.3 Identification and Implementation of Optional
Model Components
For each identified CEA in step I, the model structure was
compared with the base model and all differences in the
model structure (i.e. health states, transitions and transition
rate parameterization) were identified as optional model
components.
2.4 Quantification of Differences Induced by Different
Model Components Identified
To assess the impact of identified optional model compo-
nents from step III on analysis outcome metrics, each
component was evaluated separately and in a combined
fashion. The outcome metrics included LYG, IC and ICER.
In the separate analysis, we assessed their impact on out-
come metrics by varying one model component at a time.
In the combined analysis, model components were com-
bined according to their implementation in each of the
identified analyses. The impact of model components on
outcome metrics was quantified by computing the relative
difference from the base model (RDB) estimate as follows:
RDB ¼ MN #MB
MB
$ 100%
where M represents the outcome metrics for model N (e.g.
M1, M2, …, Mn) or base model B.
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3 Results
3.1 Literature Review
Eleven eligible publications assessing the cost-effec-
tiveness of anastrazole versus tamoxifen [19–29] were
included in this analysis. The identified differences
related to structural uncertainty are provided in
Table 1. All identified publications used the ATAC
(Arimidex, Tamoxifen, Alone or in Combination)
clinical trial [30] as a basis for implementation of
recurrence rates.
Table 1 Overview of health states and adverse events as identified in previously published cost-effectiveness models comparing anastrazole
with tamoxifen for adjuvant treatment of breast cancer
Model characteristica Base
model
Health economic analyses
Skedgel
[28]
Skedgel
[29]
Locker
[23]
Mansel
[25]
Lux
[24]
Fonseca
[19]
Rocchi
[27]
Moeremans
[26]
Karnon
[22]
Gil
[20]
Hillner
[21]
On treatment
Disease free 9 9 9 9 9 9 9 9 9 9 9 9
Disease free with
complications
9
Switch treatment 9 9 9
Off treatment,
remission
9 9 9 9 9 9
Local recurrence
Loco-regional
recurrence
9 9 9 9 9 9 9 9 9 9 9 9
Contralateral
tumour/remission
9
Metastatic disease
Metastatic disease 9 9 9 9 9 9 9 9 9 9 9
Soft-tissue
metastasis
9
Bone metastasis 9
Visceral metastasis 9
Treated relapse 9 9
Adverse events
Vaginal bleeding 9
Hip fracture 9
Experience of
adverse event
due to adjuvant
treatment
9
Need to change
treatment after
adverse event
9
Fracture (any) 9 9
Venous
thromboembolism
9 9
Several adverse events 9
Death
Death (no differentiation
for cause)
9 9 9 9 9 9
Death due to other
causes
9 9 9 9 9 9
Death due to breast
cancer
9 9 9 9 9 9
a For each distinct health state, one description was used, although the separate analyses may have used different terminology in some cases
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3.2 Definition and Implementation of the Base Model
Structure
3.2.1 Structural Model Characteristics
Health states present across all analyses and included in the
base model were (1) on treatment; (2) off treatment;
(3) local recurrence; (4) metastatic disease; (5) death due
to breast cancer; and (6) death due to other causes. The
resulting base model structure is schematically depicted in
Fig. 1.
The following transition rates were included in the base
model: (1) incidence of local recurrence from both on
treatment and off treatment (krec 9 Floc); (2) incidence of
metastatic disease from both on treatment and off treatment
(krec 9 Fmet); (3) rate of metastasis following local recur-
rence (kLoc?Met); (4) death after metastatic disease
(kMet?DtCa); and (5) a (time-varying) background mortality
(kDeathOther(t)) for patients in the health states on treatment,
off treatment, local recurrence and metastatic disease. In
addition, after 5 years of treatment, the proportion of
women present in the on-treatment health state switched to
the off-treatment health state according to the implemen-
tation in each of the identified models.
3.2.2 Parameterization of Transition Rates
Most commonly, transition rates were parameterized as
constants and were implemented as such in the base model
structure (Table 2). Only background mortality was
implemented as a discretely time-varying constant chang-
ing every 5 years [25, 31].
The publication by Mansel et al. [25] most transparently
reported parameter values and costs, and it was therefore
used as a template to obtain transition rates and costs.
Because the rates of adverse events were not clearly stated
in each of the identified articles, these were directly derived
from the 5-year results of the ATAC trial [30].
3.3 Definition and Implementation of Optional Model
Extensions
An overview of the identified models and the differences in
structure and parameterization is provided in Table 3. In
total, nine additions or changes in the model components
were identified. Three components were related to the
model structure: addition of health states (M1) and two
additional transition possibilities between health states (M2
and M3). Six components were related to choice parame-
terization (M4–M9), which are provided in Table 4. Fur-
ther details regarding the implementation of these options
are provided in the following sections.
3.3.1 Structural Model Characteristics: Metastatic Health
States (M1)
Karnon et al. [22] described a CEA in which three meta-
static health states were included instead of one. This was
implemented by separating the metastatic disease health
state into soft-tissue metastasis, bone metastasis and vis-
ceral metastasis. All different sites of metastatic disease are
associated with different death rates—for instance, the
chance of dying from visceral metastasis is higher than the
death rate for soft-tissue metastasis. To implement the
time-dependent death rates, six tunnel states for each
metastatic health state were implemented [32]. Tunnel
states were defined for each year from 1 to 5 years, and
from 5 years onwards.
The fractions for recurrence used by Karnon et al. [22]
were based on the BIG (Breast International Group) trial
[33]. We implemented these alternative health states by
using the fractions derived from the ATAC trial, because
these fractions were used in all of the other analyses.
Fig. 1 Schematic representation of the base model structure for
health economic analysis of endocrine adjuvant breast cancer
treatments. Floc fraction of local recurrence from both on treatment
and off treatment, Fmet fraction of metastatic disease from both on
treatment and off treatment, kDtO(t) background mortality rate,
kLoc?Met metastasis rate following local recurrence, kMet?DtCa death
rate after metastatic disease, kOff?Loc local recurrence rate from off
treatment, kOff?Met metastatic rate from off treatment, krec local
recurrence rate
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3.3.2 Structural Model Characteristics: Mortality Rates
(M2 and M3)
Various authors included the death rate due to adverse
events [21, 23–25, 28, 29] in their analyses. For M2,
mortality rates for three life-threatening adverse events
were included: hip fractures, endometrial cancer and
thrombosis [22]. The population at risk was defined as the
population on treatment experiencing the life-threatening
adverse events.
For M3, an additional rate for breast cancer-related
death after having a local recurrence was included,
which was identified in three different publications
[23–25].
3.3.3 Parameterization of Transition Rates:
the Recurrence Rate (M4–M6)
Three model components (M4, M5 and M6) were identified
to describe the recurrence rate. In all cases, some level of
time dependency in the recurrence rate was used, as
compared with the constant recurrence rate implemented in
the base model.
In M4, a discretely time-varying parameter with an
interval of 1 year in the first 10 years was implemented
instead of a constant recurrence rate [27].
In M5, a discretely time-dependent parameter was
included, varying the recurrence rate after 5 and 10 years
from the start of therapy [22].
In M6, a continuous time-dependent relationship was
implemented using a Weibull equation (Eq. 1) to describe
the recurrence rate [23–25], where I represents the intercept
and S represents the scale factor.
krecðtÞ ¼
t\10 year exp # S1I1
! "
! 1I1 ! t
1
I1
#1
t' 10 year exp # S2I2
! "
! 1I2 ! t
1
I2
#1
8<: ð1Þ
3.3.4 Parameterization of Transition Rates: Death Rate
After Metastatic Disease (M7)
In M7, death rates after metastatic disease were imple-
mented using tunnel states. Metastatic disease and the time
previously spent in this state were defined by using the
following series of six tunnel states with corresponding
death rates: 0–1 years, 1–2 years, 2–3 years, 3–4 years,
4–5 years, and more than 5 years in metastatic disease [19].
3.3.5 Parameterization of Transition Rates: Metastatic
Rates (M8–M9)
In component M8, the rate of having metastatic disease
after local recurrence varied according to whether a patient
Table 2 Transition rate constants used for the base model
Description Reference Parameter Units Estimate
Anastrazole Tamoxifen
Incidence of recurrence
t = [0,10] years Moeremans [26] krec Year
-1 0.02276 0.02964
t C 10 years Moeremans [26] krec Year
-1 0.02964 0.02964
Distant recurrence as a proportion of all recurrences
Metastatic disease Mansel [25] Fmet – 0.66 0.60
Local recurrence Mansel [25] Floc – 0.34 0.40
Adverse eventsa
Life-threatening Mansel [25] kLife Year
-1 0.0094 0.0132
Non life-threatening Mansel [25] kNonLife Year
-1 0.1396 0.1314
Distant metastases following local/regional recurrence Rocchi [27] kLoc?Met Year
-1 0.193
Death rate after metastatic disease
Overall survival at 2 years Mansel [25] kLoc?DtCa Year
-1 0.250
Background mortality Mansel [25] kDeathOther(t) Year
-1 b
a Adverse events were further categorized in fractional incidences obtained from the original ATAC clinical trial [30]: life-threatening: hip
fracture = 0.2090, endometrial cancer = 0.0282, thrombolytic events = 0.7627; non–life-threatening: wrist fracture = 0.0165, spine frac-
ture = 0.0103, ischaemic cerebrovascular disease = 0.0142, hysterectomy = 0.013, ischaemic cardiovascular disease = 0.0292, vaginal
bleeding = 0.0384, hot flushes = 0.2537, arthralgia = 0.2528, mood disturbances = 0.1372, fatigue = 0.1333, nausea = 0.0903, vaginal
discharge = 0.0251, use of biphosphonates = 0.05
b Background mortality rate includes time-varying variables with values changing in 5-year intervals, obtained from the UK Office of National
Statistics (2002), which were the following rates: age 65–70 years, 0.0140 year-1; age 70–75 years, 0.0247 year-1; age 75–80 years,
0.0415 year-1; age 80–85 years, 0.0717 year-1; age[85 years, 0.1615 year-1
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was on therapy. Different rates were used for the first
5 years and after 5 years of therapy [26].
For component M9, time-dependent metastatic rates
were included by using tunnel states for the first 5 years
after having a local recurrence and for years 6–15 after
having a local recurrence [22].
3.4 Quantification of Differences Induced by Different
Model Components
The base model showed average incremental costs per
patient of €3,647 for anastrazole compared with tamoxifen
and a 0.263 incremental LYG, leading to an ICER of
Table 3 Combinations of structural and parameterization differences in published articles and base model
Model Health states Mortality rate Parameterization
Rate for recurrence
incidence
Rate for death after
metastatic disease
Rate for metastasis after local/
regional recurrence
Base model Local and
metastatic
recurrence
Death rate due to
metastatic disease
Constant Constant Constant
Skedgel
[28]
Base model Adverse event
mortality rate
(M2)a
Base model Base model Base model
Skedgel
[29]
Base model Adverse event
mortality rate
(M2)a
Base model Base model Base model
Locker [23] Base model Adverse event
mortality rate
(M2)a
Local recurrence
mortality rate
(M3)a
Time-dependent Weibull
(M6)
Base model Discrete time dependence on
time in recurrence state
(M9)
Mansel [25] Base model Adverse event
mortality rate
(M2)a
Local recurrence
mortality rate
(M3)a
Time-dependent Weibull
(M6)
Base model Discrete time dependence on
time in recurrence state
(M9)
Lux [24] Base model Adverse event
mortality rate
(M2)a
Local recurrence
mortality rate
(M3)a
Time-dependent Weibull
(M6)
Base model Discrete time dependence on
time in recurrence state
(M9)
Fonseca
[19]
Base model Base model Base model Discrete time
dependence
(M7)
Discrete time dependence on
time in recurrence state
(M9)
Rocchi [27] Base model Base model Discrete 1-year time
dependence (M4)
Discrete time
dependence
(M7)
Base model
Moeremans
[26]
Base model Base model Base model Base model Discrete time dependence on
therapy (M8)
Karnon [22] Multiple
metastatic health
states (M1)
Adverse event
mortality rate
(M2)a
Discrete 5-year interval
partly time dependent
(M5)
Discrete time
dependence
(M7)
Discrete time dependence on
time in recurrence state
(M9)
Gil [20] Base model Base modelb Base model Base modelb Base modelb
Hillner [21] Base model Adverse event
mortality rate
(M2)a
Base model Base model Base model
a In addition to death rate due to metastatic disease
b Implementation could not be derived from the original publication and was therefore assumed to be unknown and base model assumptions
were incorporated
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Table 4 Structural and parameterization differences and implemented rates
Description Parameter Units Estimate
Structural model characteristics
M1: additional recurrence health states [22] Tamoxifen Anastrazole
Contralateral tumour Fcont 0.144 0.103
Loco-regional recurrence Floc 0.256 0.237
Soft-tissue metastasis Fsoft 0.048 0.053
Bone metastasis Fbone 0.256 0.282
Visceral metastasis Fvis 0.296 0.326
Death after soft-tissue metastasis
t = [1,5] years kSoft?DtCa(t) Year
-1 0.165
t C 5 years kSoft?DtCa(t) Year
-1 0.160
Death after bone metastasis
t = [1,5] years kBone?DtCa(t) Year
-1 0.245
t C 5 years kBone?DtCa(t) Year
-1 0.192
Death after visceral metastasis
t = [1,5] years kVis?DtCa(t) Year
-1 0.284
t C 5 years kVis?DtCa(t) Year
-1 0.262
M2: mortality due to life-threatening adverse events [22]
Death due to hip fracture kDeathHip Year
-1 0.040
Death due to endometrial cancer kDeathEndo Year
-1 0.035
Death due to thrombosis kDeathThrombo Year
-1 0.200
M3: Mortality due to local recurrence [23–25]
kLoc?DtCa Year
-1 0.222
Parameterization
Incidence of recurrence rates
M4: discretely 1-year interval time-dependent recurrence rate [27]
t = [0,1] years krec(t) Year
-1 0.0257 0.0190
t = [1,2] years krec(t) Year
-1 0.0384 0.0284
t = [2,3] years krec(t) Year
-1 0.0363 0.0269
t = [3,4] years krec(t) Year
-1 0.0321 0.0238
t = [4,5] years krec(t) Year
-1 0.0276 0.0204
t = [5,6] years krec(t) Year
-1 0.0238 0.0176
t = [6,7] years krec(t) Year
-1 0.0221 0.0164
t = [7,8] years krec(t) Year
-1 0.0273 0.0202
t = [8,9] years krec(t) Year
-1 0.0203 0.0150
t = [9,10] years krec(t) Year
-1 0.0138 0.0102
t C 10 years krec(t) Year
-1 0.0215 0.0215
M5: discretely 5-year interval time-dependent recurrence rate [22]
t = [0,5] years krec(t) Year
-1 0.0391 0.0289
t = [5,10] years krec(t) Year
-1 0.0288 0.0231
t = C10 years krec(t) Year
-1 0.0287 0.0287
M6: continuous time-dependent recurrence rate using Weibull parameterization [23–25]
t = [0,10] years
Intercept I1 Year
-1 9.42 9.17
Scale S1 Year 0.83
t C 10 years
Intercept I2 Year
-1 9.29 9.29
Scale S2 Year 0.83 0.83
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€13,868. The results of the analyses based on the different
components are presented in Table 5.
3.4.1 Structural Model Characteristics
Inclusion of additional metastatic health states (M1)
resulted in a 10.0 % increase in the LYG and a 7.3 %
decrease in the ICER.
Inclusion of mortality due to life-threatening adverse
events (M2) resulted in a very small decrease in the LYG
(0.03 %) and almost no change in the ICER.
Inclusion of death rates after local recurrence (M3)
resulted in an increase of 21.7 % in the LYG and a con-
sequent decrease of 16.8 % in the ICER.
3.4.2 Parameterization of Transition Rates
A discrete 1-year interval time-dependent rate of recurrence
in the first 10 years (M4) was implemented, resulting in large
differences in the LYG (?23.2 %) and ICER (-21.1 %).
A discrete 5-year interval time-dependent rate of
recurrence (M5) caused the largest difference in the LYG
(?35.4 %) and consequently the ICER (-29.3 %).
A continuous time-dependent recurrence rate parame-
terized using a Weibull equation (M6) demonstrated a
decrease in the ICER of 12.3 %, which was due to the
increase in the LYG of 0.032 (12.2 %).
Analyses with the alternative component M7, decrease
in the death rate after year of onset metastasis, resulted in
small changes in the LYG (\7.0 %) and ICER (\7.0 %).
Inclusion of time-dependent rates of metastatic disease
following local recurrence (M8, with rates depending on
the time spent in therapy; and M9, with rates depending on
the time spent in local recurrence) resulted in large dif-
ferences in the LYG (-21.3 % for M8 and -21.7 % for
M9).
3.4.3 Comparison Between Overall Published Models
The impact of the implementation of combinations of
components as presented in the published models (Table 3)
is presented in Table 6. Combining components M2, M3,
M6 and M9 (as reported in references [23–25]) resulted in
a 33.9 % increase in the LYG, ultimately leading to a
23.7 % decrease in the ICER. A combination of M7 and
M9, as reported by Fonseca et al. [19], resulted in a 13.3 %
decrease in the LYG and consequently a 18.0 % increase in
the ICER. Only incorporation of component M8, as
reported by Moeremans et al. [26], resulted in a 0.207
incremental LYG, corresponding to a decrease in the LYG
of 21.3 % and an increase in the ICER of 28.0 %. Inclusion
of component M4 for the incidence of recurrence and
component M7 following a distant recurrence, as reported
by Rocchi et al. [27], resulted in a 31.6 % increase in the
LYG and consequently a decrease in the ICER of 25.9 % to
€10,278. A combination of components M1, M2, M5, M7
and M9, as reported by Karnon et al. [22], resulted in an
increase in the LYG of 45.6 % to 0.383 and the largest
decrease in the ICER of 30.2 % to €9,683.
4 Discussion
A wide variation in the choice of model characteristics of
CEAs comparing anastrazole and tamoxifen in early breast
cancer was identified, which were associated with ICERs
varying between €9,804 and €17,966 when assessing the
univariate impact, and ICERs between €9,684 and €17,744
when considering the multivariate estimates as imple-
mented in the previously identified analyses. The range of
ICERs that were identified did not have direct implications
for the reimbursement status, when considering the
threshold of £30,000 (approximately €36,000) used by the
Table 4 continued
Description Parameter Units Estimate
M7: discretely time-dependent death rate after metastatic disease [19]
t = [0,1] years kMet?DtCa(t) Year
-1 0.500
t = [1,2] years kMet?DtCa(t) Year
-1 0.410
t = [2,5] years kMet?DtCa(t) Year
-1 0.320
t = C5 years kMet?DtCa(t) Year
-1 0.220
Rate of metastasis following local recurrence
M8: rate of developing metastasis after local recurrence depending on whether a patients is on therapy [26]
On therapy kLoc?MetOn Year
-1 0.142
Off therapy kLoc?MetOff Year
-1 0.100
M9: discretely time-varying rate after local recurrence metastasis rate not depending on whether a patient is on therapy [22]
t = [1,5] years kLoc?Met(t) Year
-1 0.124
t C 5 years kLoc?Met(t) Year
-1 0.0752
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National Institute of Health and Care Excellence (NICE)
[34]. These relatively low ICERs are related to the rela-
tively low incremental costs between both therapies.
Nonetheless, the observed differences in the LYG for the
multivariate estimates (0.207–0.383 years) could indeed
become relevant for decision making when higher treat-
ment costs are involved, which is a realistic scenario,
considering the rising intrinsic costs of new therapeutic
agents in oncology.
4.1 Model Characteristics
Ultimately, health economic model characteristics should
be biologically and clinically plausible. However, several
of the identified model assumptions did not adequately
reflect disease progression. We now discuss the specific
properties that were identified in the different CEAs.
Metastasis ultimately leads to death, and hence
describing the processes of metastasis is of key relevance
to capture the dynamics of disease progression. It has been
established that metastasis of breast cancer occurs in dif-
ferent parts of the body, with variable and time-dependent
death rates [35–40]. Therefore, the use of various meta-
static sites and time-dependent death rates is an important
consideration for description of disease progression,
instead of single metastatic health states and constant rates,
which were implemented in several of the identified
models.
Various clinical trials have demonstrated that the
majority of recurrences in early breast cancer occur in the
first 2 years after diagnosis [30, 33, 41] while hormone
receptor-positive tumour relapses can occur even after a
period of 10 years from the end of treatment [42, 43].
When considering models to describe recurrence, a con-
stant recurrence rate (base model), the reported discretely
time-dependent rates with a 5-year interval and the repor-
ted Weibull model did not specifically account for these
characteristics, whereas the 1-year interval time-dependent
rate constant did include this property.
The rate of having metastatic disease after experiencing
a first local recurrence was demonstrated to be time
dependent in several studies [30, 44–46]. Therefore,
inclusion of time-dependent parameterization after having
a local recurrence resembles natural disease progression
best.
Ultimate comparisons of efficacy are based on survival,
and therefore death rates are another important character-
istic that needs to be carefully considered. Although
inclusion of time-dependent death rates, which reflect a
decrease in the death rate after the first year of metastasis
(M7) only has a limited impact (a maximum relative
deviation of 6.84 % in the LYG), various reports have
demonstrated that patients have an increased risk of death
in the first years after metastasis, thereby supporting the
clinical relevance of implementing time-dependent death
rates [44, 47].
The use of mortality due to adverse events is scientifi-
cally well supported—for instance, after hip fractures
[48]—but its impact on the analysis outcome was shown to
be of limited magnitude in our analysis. Nonetheless, we
do consider adverse event-related mortality as a relevant
component to include in future CEAs.
Overall, from the difference in outcome metrics from
Tables 5 and 6, it becomes clear that specifically the choice
Table 5 Effects of separate individual model components on incre-
mental outcome metrics in terms of life-years gained (LYG),
incremental costs (IC) and the incremental cost-effectiveness ratio
(ICER) for anastrazole versus tamoxifen in terms of absolute values
and as the relative difference compared with the base model (RDB)
Model LYG
(years)
RDB LYG
(%)
IC
(€)
RDB IC
(%)
ICER
(€/LYG)
RDB ICER
(%)
Base model 0.263 NA 3,647.31 NA 13,868.10 NA
Structural model characteristics
M1: additional metastatic health states 0.289 9.89 3,714.90 1.85 12,854.33 -7.31
M2: inclusion of mortality due to life-threatening adverse events 0.263 0.03 3,647.31 \0.01 13,868.10 \0.01
M3: inclusion of death due to breast cancer after local recurrence 0.320 21.67 3,694.65 1.30 11,545.78 -16.75
Parameterization
M4: discretely varying time-dependent recurrence rate 0.324 23.19 3,545.91 -2.78 10,944.17 -21.08
M5: discretely varying time-dependent recurrence rate 0.356 35.36 3,490.46 -4.30 9,804.66 -29.30
M6: continuous time-dependent Weibull equation for recurrence rate 0.295 12.17 3,641.75 -0.15 12,344.92 -10.98
M7: time-dependent death rate 0.281 6.84 3,655.34 0.22 13,008.33 -6.20
M8: metastatic rate depending on whether a patient is on therapy 0.207 -21.29 3,673.04 0.71 17,744.15 27.95
M9: metastatic rate depending on time spent in local recurrence 0.206 -21.67 3,701.04 1.47 17,966.21 29.55
NA not applicable
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of the functional form (e.g. time-varying or constant) for
rate constants is an important factor for ultimate differ-
ences in the outcome metrics that are observed.
4.2 Disease-Specific Models
The aforementioned differences in model assumptions,
combined with the substantial impact on outcome metrics,
clearly illustrate the importance of the implementation of a
standardized disease-specific model for comparison of
endocrine treatments in early breast cancer. The concept of
disease-specific models, or disease-specific reference cases,
has been recently outlined by Afzali et al. [49]. Imple-
mentation of standardized disease-specific models with
adequate reflection of the underlying disease can reduce the
magnitude of variation between analyses. This is especially
relevant within oncology, given the typically small differ-
ences in efficacy and high treatment costs, which translate
into a potentially large impact of structural uncertainty.
Such disease-specific guidances have been already imple-
mented in other disease areas such as rheumatology [50,
51] and osteoporosis [52]. In the field of quantitative
pharmacological analysis, including oncology, disease-
specific models [53] and system-specific models [54, 55]
have been implemented and used to support development.
On the basis of the evaluation of structural model
components and their impact on outcome metrics, we can
identify a number of scientifically well supported compo-
nents related to structural and parameterization compo-
nents in CEAs, which significantly affect CEA outcome
measures. We therefore suggest the following conceptual
model characteristics for a standardized model for com-
parison of endocrine breast cancer treatments: (1) time
dependency of recurrence; (2) inclusion of time depen-
dency of having metastatic disease after experiencing a
local recurrence; (3) inclusion of soft-tissue, bone and
visceral metastasis health states in addition to disease-free,
local recurrence, death due to breast cancer and death due
Table 6 Effects of combined model components identified in the
previously published cost-effectiveness analyses (CEAs) on incre-
mental outcome metrics in terms of life-years gained (LYG),
incremental costs (IC) and the incremental cost-effectiveness ratio
(ICER) for anastrazole versus tamoxifen in terms of absolute values
and as the relative difference compared with the base model (RDB)
Model LYG
(years)
RDB LYG
(%)
IC (€) RDB IC
(%)
ICER
(€/LYG)
RDB ICER
(%)
Base model 0.263 NA 3,647.31 NA 13,868.10 NA
Locker, Lux and Mansel [23–25] 0.352 33.84 3,723.54 2.09 10,578.24 -23.72
Inclusion of mortality due to life-threatening adverse events (M2)
Inclusion of death due to breast cancer after local recurrence (M3)
Continuous time-dependent recurrence rate described by Weibull
equation (M6)
Metastatic rate depending on time spent in local recurrence (M9)
Hillner, Skedgel and Skedgel [21, 28, 29] 0.263 0.00 3,647.31 0.00 13,868.10 0.00
Inclusion of mortality due to life-threatening adverse events (M2)
Fonseca [19] 0.228 -15.31 3,731.68 2.31 16,367.02 18.02
Time-dependent death rate (M7)
Rate of metastasis after local recurrence conditional on time spent in
local recurrence (M9)
Moeremans [26] 0.207 -21.29 3,673.04 0.71 17,744.15 27.95
Rate from recurrence to metastasis depending on whether a patient is
on or off treatment (M8)
Rocchi [27] 0.346 31.56 3,556.21 -2.50 10,278.06 -25.89
Time-dependent recurrence (M4)
Time-dependent death rate (M7)
Karnon [22] 0.383 45.63 3,708.94 1.69 9,683.92 -30.17
Additional metastatic health states (M1)
Mortality due to life-threatening adverse events (M2)
Discrete 5-year interval time-dependent recurrence (M5)
Discrete time-dependent death rate (M7)
Rate of metastasis after local recurrence conditional on time spent in
local recurrence (M9)
NA not applicable
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to other causes health states; and (4) inclusion of time
dependency of death after recurrence. An overview of these
properties is provided in Fig. 2. Furthermore, time depen-
dency is still frequently reported as a series of empirical
discretized values, potentially leading to a suboptimal
description of time-dependent rate constants. We therefore
recommend the use of continuous functions to more
accurately describe such changes.
4.3 Guidance on Structural Uncertainty
Standardization practices, such as development of disease-
specific models, will be constantly subject to change, as the
understanding of biological and clinical properties of cancer
disease progression is constantly developing and should be
incorporated into disease-specific models. Therefore,
structural uncertainty can never be fully minimized by
means of standardization practices only, and its impact
should be appropriately considered when conducting CEAs.
However, currently, no explicit and clear guidance regard-
ing inclusion of structural uncertainty has been provided—
for instance, by national reimbursement bodies such as
NICE in the UK [3] and the Pharmaceutical Benefits
Advisory Committee in Australia [56]. The lack of such
guidance creates potential opportunities for introducing bias
that may allow for ‘optimized’ favourable outcomes [57,
58], thereby supporting the importance of developing
guidance on evaluation of structural uncertainty.
4.4 Strengths and Limitations of this Analysis
Quantitative comparisons between methodological
approaches in health economic analyses are often difficult
to perform, because of the different sources of uncertainty
that affect outcome metrics. In the current analysis, we
carefully reviewed all reported analyses and subsequently
re-implemented the identified model components, allowing
for a relatively unbiased comparison of the impact of dif-
ferent structural model components on outcome metrics.
We consider this approach useful for assessment of the
impact of structural uncertainty in other areas of CEA as
well.
We were not able to retrieve some of the model
assumptions in a limited number of cases, as indicated in
Fig. 2 Proposal for a standardized cost-effectiveness model for
endocrine treatment of adjuvant breast cancer based on adequate
reflection of disease progression. Fbone fraction of recurrences being
bone metastasis, Floc fraction of local recurrence from both on
treatment and off treatment, Fmet fraction of metastatic disease from
both on treatment and off treatment, Fsoft fraction of recurrence being
soft-tissue metastasis, Fvis fraction of recurrences being visceral
metastasis, kBone?DtCa death rate after bone metastasis, kDtO(t)
background mortality rate, kLoc?Met metastasis rate following local
recurrence, kOff?Loc local recurrence rate from off treatment, kOff?Met
metastatic rate from off treatment, krec local recurrence rate,
kSoft?DtCa death rate after soft-tissue metastasis, kVis?DtCa death rate
after visceral metastasis
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the Methods section. This finding supports the need for
increased transparency and reproducibility in the reporting
of CEAs. The use of a scripting-based frameworks war-
rants substantially improved reproducibility and transpar-
ency, allowing straightforward evaluation and external
review, and should therefore be considered for imple-
mentation in guidelines related to handling of structural
uncertainty.
A consequence of not being able to retrieve a limited
number of model assumptions was, however, that our
analysis outcome metrics did not exactly match the original
estimates—although, in our view, this was not of relevance
to our objectives, results or conclusions.
We did specifically choose not to include other types of
uncertainty (i.e. parameter and methodological uncer-
tainty). For the current analysis, the impact of methodo-
logical uncertainty can be disregarded, because all of the
evaluated models were compared in the same computa-
tional framework. With respect to parameter uncertainty, it
can be expected that this would have potentially inflated all
of the ranges in outcome metrics further, but it would have
also substantially clouded the specific evaluation of the
impact of structural uncertainty. One could, however,
imagine a case where some potentially more complex
structural model components may be associated with
increased parameter uncertainty, compared with simpler
model structures.
5 Conclusion
A systematic review of structural model properties for
CEAs comparing endocrine treatments for early breast
cancer was performed, and the associated impact of dif-
ferences in model structure and parameterization indicated
a substantial impact on outcome metrics. The wide variation
in the model structures that were identified supports the
need for (1) improved guidance on the handling implica-
tions of structural uncertainty; and (2) the need for a stan-
dardized disease-specific model for CEA of endocrine
treatments in early breast cancer. On the basis of this ana-
lysis, we have provided recommendations for a disease-
specific model for endocrine treatment comparison in ABC.
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